Literature DB >> 35122974

The radiobiology of TGFβ.

Mary Helen Barcellos-Hoff1.   

Abstract

Ionizing radiation is a pillar of cancer therapy that is deployed in more than half of all malignancies. The therapeutic effect of radiation is attributed to induction of DNA damage that kills cancers cells, but radiation also affects signaling that alters the composition of the tumor microenvironment by activating transforming growth factor β (TGFβ). TGFβ is a ubiquitously expressed cytokine that acts as biological lynchpin to orchestrate phenotypes, the stroma, and immunity in normal tissue; these activities are subverted in cancer to promote malignancy, a permissive tumor microenvironment and immune evasion. The radiobiology of TGFβ unites targets at the forefront of oncology-the DNA damage response and immunotherapy. The cancer cell intrinsic and extrinsic network of TGFβ responses in the irradiated tumor form a barrier to both genotoxic treatments and immunotherapy response. Here, we focus on the mechanisms by which radiation induces TGFβ activation, how TGFβ regulates DNA repair, and the dynamic regulation of the tumor immune microenvironment that together oppose effective cancer therapy. Strategies to inhibit TGFβ exploit fundamental radiobiology that may be the missing link to deploying TGFβ inhibitors for optimal patient benefit from cancer treatment.
Copyright © 2022. Published by Elsevier Ltd.

Entities:  

Keywords:  Biomarkers; Cancer; DNA repair; Immunotherapy; Radiotherapy; TGFβ

Year:  2022        PMID: 35122974     DOI: 10.1016/j.semcancer.2022.02.001

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   17.012


  2 in total

Review 1.  A 'Hybrid' Radiotherapy Regimen Designed for Immunomodulation: Combining High-Dose Radiotherapy with Low-Dose Radiotherapy.

Authors:  Hongshan Ji; Zhiguo Zhou
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

2.  Radiotherapy-induced oxidative stress and fibrosis in breast cancer are suppressed by vactosertib, a novel, orally bioavailable TGF-β/ALK5 inhibitor.

Authors:  Jiyoung Park; Jiwon Choi; Ilyoung Cho; Yhun Yhong Sheen
Journal:  Sci Rep       Date:  2022-09-27       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.